Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Smoldering Multiple Myeloma 1Neoplasms, Plasma Cell 1

Interventions

Cyclophosphamide 77Dexamethasone 74Melphalan 65Lenalidomide 50Bortezomib 50Peripheral Blood Stem Cell Transplantation 49fludarabine phosphate 47Busulfan 46Filgrastim 39Tacrolimus 37Antilymphocyte Serum 33Radiotherapy 30Mycophenolic Acid 30Thalidomide 28fludarabine 24Methotrexate 22Whole-Body Irradiation 21Cyclosporine 21Calcium Dobesilate 21Granulocyte Colony-Stimulating Factor 18Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 14daratumumab 11Prednisone 11Carmustine 11sargramostim 10Stem Cell Transplantation 10Sirolimus 10Rituximab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Plasma Cell × citarinostat × Clear all
NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Massachusetts General Hospital

Phase 1 Active not recruiting
19 enrolled
Plasma cell

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡